Ascelia Pharma Provides Update on the Orviglance NDA

MALMÖ, SE / ACCESS Newswire / July 3, 2026 / Ascelia Pharma AB (publ) (STO:ACE), a biotechnology company focused on improving the lives of people living with rare cancer conditions, today announced that it has received a Complete Response Letter …